Desipramine facilitation of initial cocaine abstinence

Area of Science:

• Clinical Pharmacology
• Addiction Medicine
• Psychopharmacology

Background:

• Cocaine dependence is a significant public health issue with limited effective pharmacological treatments.
• Identifying medications that facilitate initial abstinence is critical for long-term recovery.
• Previous research has explored various pharmacotherapies, with mixed results.

Purpose of the Study:

• To compare the efficacy of desipramine hydrochloride, lithium carbonate, and placebo in treating cocaine dependence.
• To assess the impact of these treatments on cocaine use, craving, and abstinence.
• To determine if desipramine is an effective treatment for initiating abstinence in cocaine-dependent outpatients.

Main Methods:

• A six-week, double-blind, randomized controlled trial involving 72 outpatient cocaine abusers.
• Participants were assigned to receive desipramine hydrochloride (n=24), lithium carbonate (n=24), or placebo (n=24).
• Exclusion criteria included dependence on substances other than cocaine; groups were matched for baseline characteristics.

Main Results:

• Desipramine significantly decreased cocaine use compared to both lithium and placebo.
• Desipramine treatment led to substantially higher rates of continuous abstinence (59%) compared to placebo (17%) and lithium (25%).
• Reductions in cocaine craving were significantly greater in the desipramine group.

Conclusions:

• Desipramine hydrochloride is an effective pharmacological intervention for reducing cocaine use and craving in cocaine-dependent outpatients.
• Desipramine facilitates the establishment of initial abstinence, a key early stage in addiction recovery.
• Lithium carbonate did not demonstrate efficacy beyond placebo for cocaine dependence in this study.